Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Techniclone (TCLN) -- Ignore unavailable to you. Want to Upgrade?

To: shero who wrote (743)	11/21/1997 5:27:00 PM
From: EZLibra	Read Replies (3) \| Respond to of 3702

Yo Shero, I'm gaining a lot of experience with these buying opportunities. I must be misspelling b-u-y or something. Oh well, if I knew what was gonna happen tomorrow I'd be at the racetrack. So who are your candidates for the Oncolym license? How about Idec/Genentech/Hoffman LaRoche? Hoffman has the deep pockets, Genentech can sell anything, and Idec will sell anything. Naah, Lym-2 is better than Rituxan anyway. Not enough attention has been paid to this;(http://www.techniclone.com/pr102397.htm}. What about some kind of prelicensing deal with Coulter? Oncolym and Bexxar would lock up radiolabled treatment of NHL and Lym-2 could be cocktailed into all three grades. What a gift-wrapped package for a Bristol-Myers-Squibb or someone. What a massive license that would command! Just speculating, of course. Any ideas Shero, Dave, John, anyone? Alys, Manfred where are you? I'm on a friend's computer (I'm on borrowed time?) but I'll be checking in this weekend. Reasonable questions and speculations are welcome, that's what this forum is for.